Q1 2025 GE HealthCare Technologies Inc Earnings Call
Of that growth that exceeded our expectations record double digit orders growth as a standalone company was driven by strength in the U S market, where we see customers prioritizing investments in imaging products with a particular focus on cardiology and oncology.
Early indications from market data shows that we gained share in a significant number of markets, where we compete.
<unk> and our strong orders growth.
In the quarter, we booked the first Sutter health orders and continued to strengthen our relationship with many other top items like our recently announced agreement with St. Lukes University Health network to drive further growth.
We saw strong momentum in backlog and continuing strength in book to Bill in the quarter.
Top line organic performance of 4% was broad based with growth in each segment and we delivered healthy margin and earnings per share performance.
<unk> said were adjusting 2025 guidance today, reflecting the estimated impact from tariffs on profit and cash.
Our sales estimates remain the same supported by a strong customer demand environment.
Let me give a more detailed view on slide four of the current global trade environment in an effort to be transparent about our view of the environment and its correlation to our business. We're showing on the chart. How we expect tariffs to impact our 2025 results if they stay at the current elevated levels.
We have conservatively assumed that the bilateral U S and China tariffs continue accounting for 75% of our total net tariff impact.
We've also assumed that U S reciprocal tariffs on rest of World announced on April 2nd returned to pre pause levels on July nine.
In Mexico, and Canada tariffs remain in place with U S. MCA exemptions for all eligible imports.
Prior to mitigation the gross impact of tariffs is estimated to be approximately $1 75 per share.
And since we initiated work on tariffs, we've moved swiftly and taken responsible and sustainable actions to mitigate over 50% of our gross exposure.
We have a strong funnel of additional opportunities for further offsets, including product and component moves which take longer to execute with.
With mitigation actions to date, we expect approximately <unk> 80 per share of net incremental impact.
This is in addition to the <unk>, we reflected in our February guidance to be clear the total impact of tariffs and our adjusted EPS guidance is <unk> 85.
Given the actions, we're taking to optimize the supply chain in 2026, we expect less than 85 of adjusted EPS impact from tariffs under the current tariff structure.
Operationally, we are strengthening our market presence and we're on track to deliver our pipeline of innovation discussed at our fourth quarter Investor day, including Radiopharmaceuticals total body, Pat photon counting Cte and next generation interventional vascular lab. These are a few of the high impact opportunities we expect.
To drive growth in 2026, now I will turn the call over to Jay to provide more detail on the quarter and guidance for the year Jay.
Jay: Thanks, Pete let's start with our financial performance on slide five for the first quarter of 2025, we reported revenues of $4 $8 billion with solid organic revenue growth of 4%.
Jay: We reported growth across each of our segments with particular strength in the U S, where we delivered high single digit growth year over year.
Jay: On a reported basis service revenue grew 3% in product revenue was up 2%.
Jay: Organic orders growth was robust up 10% year over year, the highest since our spin.
Jay: This reflected healthy underlying market demand.
Book to Bill in the quarter was strong at one nine times, we also exited the quarter with a record backlog of $26 billion up $1 $9 billion year over year, and also up $800 million sequentially.
Jay: We continued to make good progress on our margin acceleration delivering an adjusted EBIT margin of 15% in the quarter up 30 basis points year over year due to volume and productivity.
Jay: With mid single digit organic revenue growth continued margin expansion and lower interest and tax expense, we delivered first quarter adjusted EPS of $1, <unk>, which was up 12% year over year.
Speaker Change: Free cash flow of $98 million in the quarter was down $175 million from the year ago period, primarily due to timing I'll cover that later in today's call. This result was ahead of our expectations.
Speaker Change: Taking a closer look at margin performance in the first quarter on slide six adjust.
Speaker Change: Adjusted gross margin expanded 80 basis points year over year, driven by increased volume and benefiting from higher margin new products.
Speaker Change: On the cost side, we continue to drive productivity initiatives that are positively impacting margin.
Speaker Change: For instance, our imaging team has implemented a new lean management system to more effectively convert backlog.
This project has reduced our past due backlog by over $25 million, increasing customer satisfaction and improving cash flow.
Speaker Change: For the first quarter R&D investment was 7% of sales increasing 6% year over year, we remain committed to advancing our innovation initiatives and growing our product leadership positions.
Speaker Change: We continue to drive operational efficiency in SG&A, while investing strategically in our commercial capabilities, including the launch of our proprietary radiopharmaceutical blurt condo.
Speaker Change: Our ongoing optimization work and lean approach contributed to the 30 basis point year over year improvement in adjusted EBIT margin.
Speaker Change: Let's move on to segment performance, starting with imaging on slide seven organic revenue in the quarter was up 5% year over year, driven by strong execution in the U S.
Speaker Change: Segment, EBIT margin was up 130 basis points year over year, driven by productivity volume and price.
Speaker Change: This expansion versus the first quarter of 2024 was achieved while continuing to invest in R&D for new products expected to launch in the coming quarters.
Speaker Change: We continue to see robust demand in the U S and EMEA markets as we expand into large enterprise accounts.
Speaker Change: Turning to advanced visualization solutions on slide eight organic revenue was up 3% year over year with strong performance in the U S.
Speaker Change: Segment, EBIT margin increased by 10 basis points year over year, driven by volume and productivity.
Speaker Change: Our product roadmap is increasingly focused on accelerating recurring revenue with demand for digital and AI across our ultrasound and IGT product portfolios.
Speaker Change: Moving to patient care solutions on slide nine organic revenue growth was up 2% versus the prior year driven by continued growth with improved backlog execution and monitoring solutions in the U S.
Speaker Change: EBIT margin declined 450 basis points year over year due to investments tariff impact in product mix the two.
Speaker Change: <unk> is focused on delivering new product launches with higher gross margin and driving factory automation and supplier consolidations to improve margin over time.
Speaker Change: Importantly, we continue to invest in our PCI portfolio, including solutions across digital consumables and services, which is expected to enable increasing recurring revenue.
Speaker Change: Moving to pharmaceutical diagnostics on slide 10, we delivered another robust quarter globally generating 8% year over year organic growth and an EBIT margin above 32%.
Speaker Change: We were able to deliver this growth while continuing to invest in our R&D pipeline in NPI.
Speaker Change: In the first quarter, we made significant progress in executing on our radiopharmaceutical strategy we.
Speaker Change: We delivered the first commercial doses of <unk> and we saw continued growth of <unk> mill. We also completed the acquisition of the remaining 50% stake in Nihon metaphysics, which we expect to add approximately $150 million of inorganic revenue over the remaining three quarters of 2020.
Speaker Change: Five.
Speaker Change: Turning to cash on slide 11, we delivered free cash flow of $98 million down year over year, primarily due to a shift in the timing of annual employee compensation payments from the second quarter of the year to the first quarter.
Speaker Change: We also had an inventory build to support volume growth.
Speaker Change: Actively working inventory cycle times, and strategically managing our inventory amid the current tariff environment.
Speaker Change: Our capital allocation priorities remain unchanged, we repaid $250 million of debt in the first quarter of 2025 as we continue to strengthen our capital structure, we're focused on investing in organic growth and pursuing strategic M&A that aligns with our portfolio.
Speaker Change: Strategy.
Speaker Change: Finally, we remain committed to returning cash to shareholders and we're very pleased to announce today a share repurchase program authorization from our board of directors of $1 billion.
Speaker Change: Now, let's turn to our outlook on slide 12.
Speaker Change: In light of the evolving macroeconomic landscape, we are updating our full year guidance, which reflects the strength of our operational execution, while incorporating the impact from tariffs as Pete discussed.
Speaker Change: For full year 2025, we expect organic revenue growth in the range of 2% to 3%, which remains unchanged. Our strong first quarter results and solid backlog gives us increased confidence in our top line guidance for the year.
Speaker Change: Related to China, we continue to take a measured approach consistent with our comments in February we're assuming China sales performance will be negative in the first half of 2025 with a sequential improvement in the second half of the year versus the first half leading to a low single digit decline for the year.
While foreign exchange rates have been volatile based on rates where rates are today, we expect FX to be neutral to revenue compared to previous expectations of a one 5% headwind.
Speaker Change: We're continually focused on driving cost structure efficiencies that are within our control. So not at the expense of R&D, which is the driver of future innovation.
Speaker Change: For adjusted EBIT margin, we're now forecasting a range of 14, 2% to 14, 4% for the full year compared to our previous guidance of 16, 7% to 16, 8%.
Speaker Change: We estimate the incremental tariffs announced since our February guidance will negatively impact adjusted EBIT by approximately $475 million.
Speaker Change: Our adjusted effective tax rate is expected to be in the range of 21% to 22% for the full year compared to 22% to 23% in our prior guidance.
Speaker Change: On adjusted EPS, we now expect to deliver between $3 90, and $4 10.
Speaker Change: For the full year, representing a 9% to 13% decline year over year and down versus our prior estimate of $4 61.
Speaker Change: To $4 75.
Speaker Change: Guidance for adjusted EPS includes approximately 80 of net incremental tariff impact as compared to the prior guidance.
Speaker Change: Note, we have not included any potential benefit from share repurchases and our adjusted EPS guidance.
Speaker Change: Lastly, we now expect to deliver free cash flow of at least $1 2 billion for the full year given the impact of tariff payments. This is compared to our prior expectation of at least $1 $75 billion.
Speaker Change: Aligned with the timing of the liquidation of higher cost inventory in the P&L, we expect a more significant impact from tariffs in the second half of 2025 versus the first half.
Speaker Change: We thought it would also be helpful to provide our view of performance for the second quarter of 2025, we currently expect year over year organic revenue growth for the quarter to be in the range of 1% to 2% <unk>.
Speaker Change: Including the impact of tariffs, we expect a high single digit decline year over year on adjusted EPS overall.
Speaker Change: Overall, the global trade environment improves and these tariffs are not in place for the entire year or rates decrease in aggregate, we would see a benefit to adjusted EBIT adjusted EPS and free cash flow versus what we've shared today.
Speaker Change: I want to thank our global teams for continuing to innovate and deliver financial results as we manage through a very dynamic global environment.
Speaker Change: We have the right plans in place to manage the near term and we are focused on delivery and growth for the long term.
Speaker Change: With that I'll turn the call back over to Pete Pete.
Speaker Change: Jay Let's move now to some innovation highlights in our business I've talked in the past about our evolution from being an imaging an equipment company to a healthcare solutions provider.
Speaker Change: Evolution is deeply rooted in innovation and as you can see on slide 13, some of the key Npi's launched in the first quarter are helping to enable personalized care and cardiology throughout the patient journey.
Speaker Change: I attended the American College of Cardiology meeting, where we officially launched for Kadow. Our first of its kind pet myocardial perfusion imaging agent to detect coronary artery disease I am excited to share that we received CMS pass through pricing for this novel Tracer and we're on track with our planned roll.
Speaker Change: Got it.
Speaker Change: At ACC, we also introduced a dedicated cardiac Cte system Revolution, five focused on a variety of cardiac tests, including coronary Cte and geography.
Speaker Change: These types of exams are expected to increase now that global guidelines and reimbursement levels make it more financially viable.
Speaker Change: To wrap up on slide 14, we're very pleased with our strong start to the year with record orders and strong top line growth driven by performance across all of our segments.
Speaker Change: <unk> have a positive sentiment around existing GE healthcare solutions and are excited with our pipeline of new products and there is strong demand in many of our markets that we serve.
Speaker Change: I am proud of how our teams are executing on our precision care strategy and going above and beyond and dealing with the macro challenges.
Speaker Change: Our commercial teams are winning and we're making a difference in the eyes of our customers.
Speaker Change: As we discussed earlier, we have dedicated teams focused across our supply chain executing actions to reduce our tariff impact today and into 2026. Some plans. We can implement quickly others will take months at the same time, we're carefully managing discretionary expenses across the company.
Speaker Change: <unk>, while maintaining long term innovation investments.
Speaker Change: We will continue to focus on what we can control to protect margin earnings and cash flow.
Speaker Change: Before we open up the call for questions I'd also like to welcome Jeanette bankers, who is joining us in may as our new CEO of patient care solutions <unk> is a well respected global leader in Med Tech who brings more than 30 years of experience with public companies. We're thrilled to have her as part of the team and we look for.
Speaker Change: To her leadership contributions and advancing our precision care strategy with that let's open up the call for questions.
Speaker Change: Thank you Peter I would like to ask participants to please limit yourself to one question and one follow up operator, let's please open the line.
Speaker Change: Thank you and as a reminder to ask a question. Please press star one on your telephone and wait for your name to be announced.
Speaker Change: To withdraw your question. Please press star one again.
Larry: And our first question will come from Larry <unk> from Wells Fargo. Your line is open.
Larry: Good morning, Thanks for taking the question and congrats on a strong start to the year here.
Speaker Change: Yes, I wanted to ask one on tariffs and one on China, Let me start with the tariffs.
Speaker Change: Jay I'd love to hear more about the tariff impact from you.
Speaker Change: <unk> 85 cents in 2025, it's a partial year.
Speaker Change: It looks like you expect the impact to be lower.
Speaker Change: 85, <unk> next year in 2026, how are you achieving that and how would the pharma tariffs impact that that second talk about the cadence of the tariffs I assume the impact is greatest exiting this year given inventory turns thanks.
Speaker Change: Sure.
Speaker Change: Larry as it relates to tariffs. This year, we estimate 85 cents of impact which is predominantly centered in Q2 Q3 and Q4.
Speaker Change: If the tariffs remain at LD elevated levels that they are at today in terms of an actual tariff levels in place. Our expectation is that next year, we will be below 85.
Speaker Change: And really what we've done to date is a lot of sort of more straightforward mitigation. So duty drawback U S. MCA compliance bonded logistics routes all of those are more simpler and more straightforward they require work, but that's the predominant.
Speaker Change: Tenant number that were seeing run through in terms of offsetting impacts in 2025 as.
Speaker Change: As we look at 2026, there are a number of incremental moves that we would make.
Speaker Change: And remember our company coming out of Covid, we did a lot of work on sourcing and making our products where they are consumed and we did a lot of work on dual sourcing we would continue and accelerate some of that so we would look to shift to manufacture more local for local there are a number of.
Speaker Change: Dual make opportunities for us and then from a supplier standpoint, we're currently hard at work looking at multi sourcing.
Speaker Change: Our supply and so those are some of the tactics that are that allow us to mitigate even further the impacts in 2026.
Speaker Change: Now you asked a question around cadence of impact in the first quarter, we had a very small impact from tariffs.
Speaker Change: Maybe around $10 million, but as we move into the second quarter and the third and fourth quarter. The impact is more dramatic in the second quarter of this year, we expect.
Speaker Change: Less than a $100 million of impact a little bit less than $100 million and then in the third and fourth quarters.
Speaker Change: Around $200 million of impact.
Speaker Change: And a lot of that has to do with the timing of when higher cost inventory runs through the P&L. So as we look at 2026, the first quarter of the year, we will have a similar level of impact to the fourth quarter, but then the mitigation that we're putting in place start to rapidly impact that as it draws.
Speaker Change: Down over the course of the rest of the year.
Speaker Change: So really that's I think that that hits. The question in terms of timing of cadence this year, along with the impact next year.
Jay: That's super helpful. Jay.
Jay: And then on China, It looks like it improved significantly in Q1.
Jay: Color on what Youre you gave the cadence that you expect this year just color on what Youre seeing there and how youre thinking about the potential impact of Edp. Thank you.
Jay: Hey, Larry It's Pete look I think and as we said in prepared remarks, China hasn't material materially changed from what we've laid out from our expectations even back to as we've talked about in Q4, and I think kind of confirmed and in.
Jay: In the first quarter discussion, we still expect mid single digit decline in the first half.
Jay: We would expect probably Q2 to be one of the more tougher quarters, just relative to how we look at the compares and the challenges.
Jay: Then sequentially improve in the second half and there is no indications that we've seen market wise that thats changed I know others have reported potential.
Jay: Potential rebounds different messaging in the marketplace I think we've been rather consistent here and we watch a lot of how the tender money is being released that we judge that on so.
Jay: That is how we see that playing out you ask about GBP part of our strategy and plans. This year were to factor that in again.
Jay: <unk> is a very specific item on this value based procurement, but we've seen bulk tender buys over the years. These just become more intense bulk tender buys by province.
Jay: We have specific configurations that we offer in those type of construct our distribution network and the cost of go to market is different when we enter into those deals. So I would say at this point in time, it's pretty much aligned to what we had assumed relative to 2025, China.
Larry: Alright, perfect. Thanks, so much thanks Larry.
Speaker Change: Thank you.
Speaker Change: And our next question will come from Jason Bednar from Piper Sandler Your line is open.
Jason Bednar: Hey, good morning, nice quarter everyone.
Speaker Change: I appreciate all the details you provided here today on the tariff dynamics like Larry I want to focus first on that topic in the mitigation efforts that are not contemplated in todays guidance.
Speaker Change: You already had cost saving efforts in motion for this year and obviously plan for future years are the actions you're taking to mitigate tariffs. These are probably more in the 26 variety of than some of the immediate things youre doing here, but are these a pull forward of actions that were contemplated in your <unk> I guess more directly on a long term basis like how should we be think.
About the net effects of tariffs and mitigation efforts in the context of the <unk> that you provided at the Investor day back in November.
Speaker Change: Yes, well look I mean, it's obviously early there is a lot of variables that are out there, but our views on the medium term here, we laid out investor day have not changed just to be clear about it I think the pathway might be slightly different.
Speaker Change: Obviously, as we lay out strategies and plans. This wasn't fully laid out maybe a year ago, but we have many levers that we can pull to be able to deliver on this this business has tremendous margin and growth potential. So nothing has changed from that and so look we're taking a prudent view of the current trade ins.
Speaker Change: Environment and the impact on the business I think you've seen the numbers we have laid out we basically said that the numbers. We are discussing stay at these elevated levels.
Speaker Change: A world China throughout this whole time period.
Speaker Change: As we move into these scenarios, even if those rates come down.
Speaker Change: Going to be quite aggressive on what we can do to make local for local and different marketplaces move aggressively as Jay said on dual supplies scenarios and also how we take a look at our overall configuration construct to better position us as we go forward, but I look I feel quite good about our.
Speaker Change: Margin potential of this business and ultimately over the long term what that means from how we how we view the profit capability as well as the growth capabilities of GE healthcare.
Speaker Change: All right very clear. Thank you and then for my follow up.
Speaker Change: Lot of other changes implemented by the current administration beyond just tariffs, including budget cuts and headcount reductions that key health care agencies have you seen any downstream impacts on your business from these actions.
Speaker Change: Your interactions with the FDA changed at all.
Speaker Change: Sorry to pack and a couple of here, but really interested to hear how you're thinking about the photon counting CP submission. That's planned for later this year and if that submission timing, it's still on track in light of all the changes at the FDA.
Speaker Change: Yes, Jason Thanks.
Speaker Change: I would say in short we haven't seen any impacts from any of the administrative changes at this point, whether they be on the cost or or other items at this point in time.
Speaker Change: Obviously, there's a lot of concern I think the NIH funding discussions hits many of the academics.
Speaker Change: Could there be changes there I suppose it could but we havent seen anything specifically that has come through from that and from the FDA standpoint at this point in time, there were some bigger cuts theyre actually where employees brought back in from our submissions on 500 10-K's, primarily in what we're counting on.
Speaker Change: We currently don't see any delays from from that standpoint, now obviously those things could change based on how that plays out but at this point in time, we as far as speaking for our plans of new product approvals, how we see the market and how our customer base is prioritizing their spend we haven't seen any specific.
Speaker Change: Impact that would be notable I'd say at this point in time.
Speaker Change: Alright very helpful. Thank you Pete thanks.
Speaker Change: Thank you. Our next question comes from Vijay Kumar with Evercore ISI. Your line is open.
Vijay Kumar: Hey, guys. Good morning, and thank you for taking my question maybe.
Vijay Kumar: First one sort of related to China and tariff.
Vijay Kumar: Helpful comments there.
Vijay Kumar: 75% of.
Vijay Kumar: <unk> had been screen.
Vijay Kumar: Related to the China U S. What is.
Vijay Kumar: What portion of that is U S and China versus China to U S. I think there was some clock, maybe if exemptions from China.
Vijay Kumar: Any update on that I think from China to U S.
Vijay Kumar: Products are you importing that then there was talk of exemptions under anixter for radio Pharm.
Vijay Kumar: And if these tariffs where some of these headwinds were to be rolled back.
Vijay Kumar: What is the upside the guidance here.
Vijay Kumar: Sure Vijay as we said in the prepared remarks total tariff impact.
Vijay Kumar: <unk> $500 million for the full year and the bilateral China tariffs are the most significant impact for us at around $375 million. That's roughly 65 of the 85 of impact on that we're experiencing and it really it really goes both ways.
Vijay Kumar: As we do ship a fair amount of product from U S, China and vice versa.
Vijay Kumar: We have not included any unplanned exemptions and we're not really seeing a positive impact from exemptions nor are we counting on that but I mean, just to just to frame. It for you and I'm not suggesting that we think this is a likely scenario, but in one hypothetical scenario.
Vijay Kumar: If the U S. China agreement, let's say that went into effect on may one.
Vijay Kumar: <unk> had both sides improve.
Vijay Kumar: <unk> points.
Vijay Kumar: So China goes from 45 from the $145 a day to 45 in China exports go to 25 from 125 today, we estimate that this would be a benefit to EPS of approximately <unk> 40 for the year. So it's a big number for US. These are large tariff numbers that we have.
Vijay Kumar: In place so we'll watch very closely of the scenario and how this plays out maybe Pete if you would add something.
Pete: Yes, I would say Vijay I mean, we're a big exporter from the United States into China.
Pete: We've been.
Pete: Doing this for a long period of time, some of our higher technology and X-ray generation.
Pete: Some of our componentry, and MRI and stuff and so that's a big part of the number that we actually export into that and so that gets hit by those J said the 125 tariff and then there are select components in areas that we pull out of China that feeds other plants around the world and so even though we may manufacturer.
Pete: The whole product in the United States or other areas you may have 20% of the components coming from one of these countries with the high tariff areas and so that's why the concentration exists and obviously if there is changes that take place in there that will have a bigger benefit if it doesn't we have opportunities and plans to do much more local for.
Pete: Local.
Pete: And actually work our supply base across our 43 plants.
Pete: To feed that and when I talk about it takes months to get there those are the things I'm, referring to but we have all of those levers in front of us if we need to go there and thats part of our plan to be able to to be able to execute on that.
Pete: That's helpful.
Pete: Maybe my follow ups here on the free cash.
Pete: Lowered by.
Pete: Maybe a half a billion.
Pete: Is that all Kathryn packaging set tariff was half a billion head or anything else going on in the free cash flow.
Vijay Kumar: Yeah. Thanks Vijay.
Vijay Kumar: Just just as an aside we were pleased with the free cash flow in the first quarter.
Vijay Kumar: And it was really nice start to the year, we did lower to at least $1 2 billion and this was exclusively due to tariff payments basically it's the P&L impact that I described there is some benefit from cash tax impact.
Vijay Kumar: From that we pay but then the offset is.
Vijay Kumar: The higher costs and tariffs impact inventory and cash flow first before they're liquidated to the P&L. So what we're seeing is the buildup in this year and Thats what causes on this $550 million reduction that we've highlighted at this point there is no other change.
Vijay Kumar: As to free cash flow, we are continuing to stay very vigilant and we think the business is a very strong cash generator and.
Vijay Kumar: And we're still driving operational working capital improvements, but.
This tariff impact is something that we're working through.
Vijay Kumar: Thank you guys.
Speaker Change: Thank you. Our next question will come from Robbie Marcus from Jpmorgan. Your line is open.
Speaker Change: Oh great.
Vijay Kumar: That's on a good one.
Speaker Change: Q.
Speaker Change: Two from me.
Speaker Change: Wanted to ask.
Speaker Change: First on <unk>.
Speaker Change: And how that's going.
Speaker Change: And then.
Speaker Change: I'll, let I'll ask second here just sort of the.
Speaker Change: The environment in China, we saw the anti dumping.
Speaker Change: Allegations get announced not against GE healthcare, specifically, but just on the industry.
Speaker Change: How are you viewing that any expected change how do you think you fit in there and just a quick clarification on <unk>.
Speaker Change: Whether it.
Speaker Change: Pharmaceutical diagnostics are included or excluded in tariffs.
Speaker Change: Here I think you've touched on it but.
Speaker Change: Just wanted to get a firm answer.
Speaker Change: Thanks, a lot I appreciate it.
Yes, Ravi thanks, Thanks for the questions, maybe I'll start out with Florida, Colorado.
Speaker Change: And then we'll talk a little bit about the next components that you had so look up Riccardo we're feeling quite good about it.
Speaker Change: As we mentioned in the comments, we're pleased with the progress we've talked about launch in April we've hit that we're on track.
Speaker Change: <unk> talked about roughly $30 million of revenue in 2025, and we're well aligned up to that.
Speaker Change: It takes time to ramp these again as we bring up the sites and because it is a radiopharmaceutical.
Speaker Change: Manufacturer local to the relationship of where its consumed and so we're expanding our CMO contract manufacturing organization throughout the U S. I would say that is right on track to where we are we're north of a dozen sites and that will double by the end of the year, but the feedback has been good clinically.
Speaker Change: The image quality superior or really anything out there on the myocardial profusion front.
Speaker Change: Ultimately the specificity sensitivity to take <unk> disease.
Speaker Change: We'll come through based on that there is benefits of the half life in distribution versus the predicate product so to speak today rubidium and the generators. So all of the scenarios that we've laid out look good I'd say a couple of big things we've done the first dosing here.
Speaker Change: In mid February it's gone well commercial launch as I mentioned at the American College of Cardiology, a lot of interest there and then this pass through status from CMS on reimbursement is big deal and that was approved on April one so we're off and running and things.
Speaker Change: Things look good there's a lot of interest within the product.
Speaker Change: Your next question was on.
Speaker Change: So there was a question on.
Speaker Change: The China market and some of the.
Speaker Change: Antidumping, Yes look I think across the.
Speaker Change: The globe I think from a standpoint of sentiments with us or American companies and stuff, we haven't seen any.
Speaker Change: Fax or anything relative to market as we've mentioned we've seen that aligned.
Speaker Change: At this point about this anti dumping discussion, but yes, there was a communication it stemmed from a complaint from a private company that named a significant amount of multinational companies from around the world.
Speaker Change: And included not just again, obviously us I think thats really important it didn't originate from the government. It originated from a complaint of a private company and so we don't believe this this investigation is material risk to our business in China.
Speaker Change: Back on I'd say just.
Speaker Change: April six early us among other companies had a meeting with the Ministry of Commerce.
Speaker Change: And it underscores kind of the discussions about fair treatment and there were positive comments expressed about us obviously not being targeted we've had numerous discussions obviously with 90 officials.
Speaker Change: Since the tariffs and things are taken off as well in and have seen support to be able to continue to be obviously, an important player within that marketplace. So again I don't I don't see anything that comes out of there of course of normal business relative to things that happen in different marketplaces, and your last point I think Ravi was on.
Speaker Change: Pharma and the tariff discussion Jay do you want to his sure. So so Ravi we haven't included any potential $2 32 tariff impacts in the guidance. Our approach is to include tariffs that have been announced are quantifiable or.
Speaker Change: Our Pds RPX business has products that are principally used in tandem with imaging equipment. So it's not clear at this point, where that would fall on whether these products would be in scope of potential $2 32 tariffs of our pdx business has positive pricing dynamic. So we'll have to watch that so.
Speaker Change: We'll watch this as it evolves.
Speaker Change: <unk> addressed it appropriately.
Speaker Change: I appreciate it I think we're all trying to figure out some of the nuances here. So if you don't know I'm pretty sure we don't know either.
Speaker Change: Thanks, a lot.
Speaker Change: Yeah.
Speaker Change: Thank you. Our next question will come from David Roman from Goldman Sachs. Your line is open.
David Roman: Thank you and good morning, I wanted just to start on <unk>.
David Roman: Tariffs I feel like I know you've covered this extensively but.
David Roman: There are a lot of moving parts here I mean, some of it is clearly just math.
David Roman: Some of it is operational so can you help us kind of understand the magnitude of mitigation actions that are already in place versus those that need to be implemented and then in that same context, how you're thinking about sustaining investment in the business are in SGA and R&D than I have.
David Roman: A follow up on the strategic side.
David Roman: Sure So first as it relates to.
David Roman: SG&A and R&D.
David Roman: We're obviously very focused in this environment on controlling spending so things like travel head count we're very disciplined on these areas and Furthermore, with respect to our productivity initiatives, we are continuing and intense focus on those areas.
David Roman: At the same time, we're protecting key investments in R&D in terms of the pipeline and how this is going and we're also protecting critical investments in sales and marketing.
David Roman: To support some of these great launches that we have so that's the philosophy on SG&A and R&D and spending controls I would say that's really what we have in place. The only thing I would add is we are earmarking a portion of money for.
David Roman: The fact that there will be spending that takes place. This year that supports incremental mitigation efforts next year in.
David Roman: In terms of tariff offset so we've allocated some money to that in the second half of the year.
David Roman: Now as it relates to your question on mitigation and tariffs we've done we've done a significant amount of work and we have a very clear line of sight.
David Roman: To essentially all of the savings that we've earmarked for this year and so that includes things like duty drawback completed U S. MCA tariff code exemptions, we spelled out some of it on this on the slide but it's safe to say we have a very long project plan that supports this and then as we go to next year we have.
Have a very long funnel of opportunities, but some of the implementation will depend upon the final nature of the tariff agreements that are in place and so we have to wait and see a bit how things settle out before we lock in on all of those but as I said, we have a very solid funnel that's outlined to.
David Roman: Support the achievement of next year's number Pete what would you add.
Pete: Yes, David I think Jay you covered it well, but just to give some more examples here is we obviously want to see how the tariff matrix plays out around the world because you don't want to initiate a move until you actually understand what that rate may look like where you would move to another country Theres. Some no regret moves Jay touched on those but the <unk>.
Pete: Reorders if things are we make a lot of the same products in the same country. So you can actually throttled down one planned throttle up another we're already in the midst of doing that I think in our vascular business in our in our molecular imaging business and our <unk> business, we have the potential to do all of those type things. The next as we source and make components.
Pete: <unk> in many different places these are from our own four plants, and so where we might be making something in the U S to go to another area or some other country to come to Western Europe or the U S. We can actually change the mix of that and so in some cases that the exact product might not be there in a transfer is pretty straightforward because all of the core.
Pete: Since these exists to do that and the third would be we have a big supply base and many of our suppliers are global suppliers and they are making it in this country versus that country. We can have them switch and ramp that up all of those are the games and play and they take multiple months to move but that's why we have confidence in second half of this year and going into 'twenty six that we.
Pete: We can.
Pete: Significantly larger mitigation efforts.
Speaker Change: I appreciate all the color and maybe just a follow up here you know considering what looked at obviously broader market dislocation here. How are you thinking about M&A isn't this a prime environment to kind of accelerate those efforts is.
Speaker Change: Whether they're short term disruptions create some some obviously noise around what you've got you guys might otherwise consider long term structural winners in categories like monitoring our diagnostics.
David Roman: Yes, David.
David Roman: Youre right on I mean, we've been very clear about our capital allocation strategy is.
David Roman: <unk> investments and then finding the right types of tuck in M&A, We obviously announced other levers that we're executing on but M&A is a critical one for us.
David Roman: We've got a strategy, we've talked about about expanding our topline growth as well as growing our margins. So as we look at.
David Roman: Opportunities to bring into the portfolio, that's absolutely right and I think in this window of time.
David Roman: We might be able to find some interesting components to plug into the into the our structure I would say.
David Roman: Most interested right now finding assets youre going to bring additional growth that's been a big part of our discussion of being a consistent mid single digit grower moving to the higher end of that range and so we have a really nice portfolio of opportunities you'd never know, how they'll play out but plugging those into the system to drive faster growth.
David Roman: Is what we're looking for.
Speaker Change: Great. Thanks, so much for taking the questions.
David Roman: Alright, thank you.
Speaker Change: Thank you. Our next question will come from Joanne Wuensch from Citi. Your line is open.
Joanne Wuensch: Good morning, Thank you for taking the question and for giving US all of this information.
Speaker Change: I have two questions I'll, just kind of upfront.
Speaker Change: Capex environment, particularly in the hospital has raised some questions with Susan I'd Love to get your view on what Youre seeing in the United States as well as outside the United States and then my second question has to deal on Perm counting it sounds like that's still on track for 2025 submission in 2026 approve.
Speaker Change: <unk>.
Speaker Change: Do we think about that product once it comes to market and accelerating revenue. Thanks.
Speaker Change: Sure. So we were very pleased with the performance in the first quarter as it relates to the hospital capital environment, We saw a very robust demand coming from the United States and also interestingly, we saw really robust demand in Europe, but that's an area that if you look over the last year.
Speaker Change: A year and a half of the growth rate had slowed a little bit but as we looked at.
Speaker Change: The order book in the first quarter in Europe, we did see some acceleration there as well. So we were we were definitely pleased with the environment and that showed up in a 10% order growth in the book to Bill that we reported now as you know we also supplement with our customer survey that we do internally when we look at external surveys as well.
Speaker Change: And what I would say is we continue to see a very constructive demand environment at this point.
Speaker Change: Customer budgets a lot of them were set earlier in the year and we haven't observed any significant cancellations or deferrals in response to the global trade environment.
Speaker Change: And we're continuing to see areas like imaging set as a priority with respect to our hospital customers. So I think I think the environment is good we've got a record backlog, which.
Speaker Change: Which increased quite substantially year over year. So that was a great great start to the year with very solid book to Bill. So I think I think the environment is constructive at this point.
Speaker Change: Yeah, and I think just to add some additional points as I talked to a lot of big <unk> here in the U S. Just spend some times with ministries of health around the world.
Speaker Change: The idea about imaging and much of our critical care equipment being.
Speaker Change: Indisputable kind of tool to actually drive productivity in the face of shorter.
Speaker Change: Our less resources is a big deal you can do a scan an ultrasound or a C T and reduce the time to diagnosis significantly and when you look at the value we represent with some of the reimbursement scenarios, where the cost to serve most of these products pay for themselves in a year or a year and a half.
Speaker Change: So with a life of six to seven years, it's a really strong economic deal and so when you see capex surveys come up we typically rise to the top of the list heavily tied to that point.
Speaker Change: And I think John you had a question on photon counting yes, we're well on track to our submission times, we're on track to what we communicated relative to the introduction windows as well. So we feel quite good about it again, we have a differentiating approach on how we're looking at our photon counting.
Speaker Change: There's obviously a lot of people talking about bringing out technologies most of the technologies that they are bringing out or kind of me too with the existing product on the marketplace and that detector technology. We believe the focus on deep silicone and spectral imaging is really the game changer here, which is this idea to see.
Speaker Change: Molecular changes and what's happening at a cellular level in Cte imaging, which to date has not been really demonstrated and then bring all of the other benefits as well higher special resolution and Joseph efficiencies as well so feel good about our technology and our platform and to the point. These are.
The kind of programs that through all of the challenges that are happening macro we're making sure. We protect because these are the launches that are going to have a strong impact for us here in 2006 and below.
Speaker Change: And beyond so thank you.
Speaker Change: Thank you.
Speaker Change: Thank you. Our next question will come from Craig Bijou from Bofa Securities. Your line is open.
Craig Bijou: Good morning, guys. Thanks for taking the questions I wanted to go back to China for for.
Craig Bijou: For my first question I appreciate the comments on the anti dumping.
Craig Bijou: There's also the rare element.
Craig Bijou: Exportation limitation, so and I know you're pdx many of your PBX products use use rare elements. So.
Craig Bijou: I wanted to understand kind of what risk do you see from that potential and then maybe just broadly you sound Pete you sound like you're pretty confident that there's no disruption to the overall business in China or your business in China from from these potential trade wars.
Craig Bijou: But just wanted to understand how you see that playing out maybe a little bit longer term and if there is any impact.
Speaker Change: Yeah, Craig Thanks for the question. So look on the first one on the rare Earth elements.
Craig Bijou: We don't see.
Speaker Change: Ultimately long term bigger issue.
Speaker Change: We've had some contrast agent.
Speaker Change: Ponant Gad and stuff that we have supply from.
Speaker Change: Multiple locations, but obviously over time, our ability to kind of shift and manage that will we'll deal with that.
Speaker Change: We typically carry in that case from an API standpoint, a significantly longer window of supply over a year. We've traditionally done that so I don't I don't see any specific issues long run there we do have and we've talked about at our Investor day, we actually have a new product that is in clinics.
Speaker Change: Development right now that actually would.
Speaker Change: We think actually transform imaging within contrast space for MRI is manganese manganese product and then on there is certain components in detectors and things of that nature, but there are other sources and in the spirit of longer term multi sourcing scenarios those all fit into that to make sure we could secure.
Speaker Change: But at this point, we arent concerned specifically about that I think your second question was relative to kind of the sentiment in China in the market and the ability to compete is that was that your question.
Speaker Change: Yes, that's it.
Speaker Change: Yes look.
Speaker Change: Again, as we look at that marketplace, particularly in China.
Speaker Change: We play as a local player as much as possible. We again source significantly amount of local product just to be sold within that marketplace met a lot of those changes in the last year, we have relationships.
Speaker Change: With with Big players that are actually an indigenous into the market and so in some cases, we actually go to market under under those names in the JV and I think as the markets evolve our strategy to actually be more local probably will play out that way to be successful, we're not seeing sentiment it.
Speaker Change: This point in time that says for against GE healthcare.
Speaker Change: That we wouldn't Bayou for X y or Z reasons, but obviously this is why we've been we've been obviously very focused on making sure that we're seen as a local player that has been a critical part of that marketplace. I also would just say is that from a standpoint of China in general it being the second largest healthcare market in.
Speaker Change: The World are ultimately will be is a key reason that finding the right solution to be ongoing success. There is a reason that we obviously still stay focused on that marketplace.
Speaker Change: I appreciate it.
Speaker Change: Just as a follow up obviously the strong.
Speaker Change: Strong order growth in Q1 strong imaging revenue.
Speaker Change: Was any of this potentially a pull forward for some of the mitigation actions that you have been working on on the tariff side or anything else, maybe one time to call out during the quarter.
Speaker Change: Zero pull forward.
Speaker Change: There is no someone saying, hey, I want to buy early before prices.
Speaker Change: No this is pretty much stable operations.
Speaker Change: It's really a great example, particularly when you look at the book to Bill in the orders performance.
Speaker Change: The excitement customers have really globally, not just about our products, but how our products our services and our solutions are brought to folks from.
Speaker Change: Our sales teams I think both here in.
Speaker Change: The U S internationally, even our China team I get a lot of great feedback from customers, saying about the humility of our teams and the.
Speaker Change: Can do attitude about what is my problem.
Speaker Change: How can I help you and that sets us apart from maybe other suppliers that maybe aren't as I'd say open to solving a specific customer's problem and that's really making a difference and again I think if you look at the performance we had in the first quarter really record level growth that we've been able to put up and so I'm quite optimistic that even through.
Speaker Change: The challenges are happening macro youre going to continue to see GE healthcare put up some good growth.
Speaker Change: Understand thanks for taking the question.
Speaker Change: Yeah.
Anthony Petrone: Thank you and our last question will come from Anthony Petrone from Mizuho Financial Group. Your line is open.
Anthony Petrone: Thanks for taking my question and congratulations to the team, we're counting $550 billion I guess of offset here and so Jay Pete and the rest of the team I'm sure. This was a lot of work. So obviously congratulations on all of that sticking with tariffs and then on for Caito.
Anthony Petrone: On tariffs, there's a lot on semiconductors.
Anthony Petrone: Going back and forth between U S and China.
Anthony Petrone: I'm, assuming semiconductor impacts are reflected in your net 85%.
Anthony Petrone: Impact.
Anthony Petrone: So that'll be the first question, just where the semiconductor sitting all of this.
Anthony Petrone: And you're calling out less of an impact in 2026.
Anthony Petrone: No. It's early days you had a lot of offsets here pricing opex as other funnel initiatives in 'twenty six is there any early estimate as to maybe where that can go is it safe to assume maybe it gets cut by a third cut by half.
Anthony Petrone: One quick follow up on flip caito.
Anthony Petrone: Sure maybe I'll start as it relates to semiconductors. It is not one of the most significant important items.
Anthony Petrone: We do use related products and some of our devices. So we'll continue to watch this area we've reflected it appropriately.
Anthony Petrone: As it relates to what we can achieve next year.
Anthony Petrone: We're working feverishly reductions of tariff impact side I hope you can see that in the material that we shared today at this point, we see a pathway to below 85.
Anthony Petrone: We are we're going to update this every quarter when we talked to all of you because it is such a substantial driver for us and it's not clear yet what will be able to achieve in the final analysis, but we feel very good about holding the impact that the 2025 level or better at this stage Pete.
Anthony Petrone: I think to the point.
Anthony Petrone: We're.
Anthony Petrone: We're obviously doing lots of things talking to administration talking on many sides of the world relative to rates, particularly with the concentration that we have the component moves in the supply piece I hit the three areas, where we're going hard on that and all accounts and so that's the biggest component of offset as the physical changes.
Anthony Petrone: And the moves in chase talked on this before I mean, G&A more and costs and things like that we're going to be responsible with but we're also making sure that we fund the heavy growth.
Anthony Petrone: We have room in a large company like that to be able to manage that.
Anthony Petrone: And with price at this point, we haven't built a lot of price offset and here. We are positive price player. We've had positive price in the first quarter, even with GBP and pressure within China, We've put up positive price and so we have that lever to do more but candidly, we're trying to offset as much as we can with cost.
Anthony Petrone: So that from a effect to our customers it's managed.
Anthony Petrone: To offset as much as we can but as things go on longer obviously price will have to be a key factor that will have to take a look at if tariffs exist at a high rate for a longer period of time.
Anthony Petrone: That's helpful input caito that they estimate that the company has out that $30 million for 2025 and $500 million for 2028, and maybe just to refresh on those assumptions and when you think about.
Anthony Petrone: Potential upside to that.
Anthony Petrone: Is that more contingent on just rate of adoption.
Anthony Petrone: The nuclear medicine level or do you have a capital component to that that needs to be unleashed.
Anthony Petrone: More pet scanners out there in the marketplace. Thanks.
Anthony Petrone: Anthony I think it's more so about just the adoption and the conversion I think in the cardiology space because you know, there's clearly opportunity for more systems to go out there, but we don't see that as the gating factor.
Anthony Petrone: The uptake a lot of this is there's multiple steps on how you run a radiopharmaceutical department. We have success type managers, we're adding folks of that nature that can help convert it so.
Speaker Change: We're optimistic that that can step up but look it comes back to a couple of things. One is the reimbursement positive I mentioned pass through that's there is the product differentiated we believe so better image quality be able to see false positives false negatives more effectively than the predicate products that are out there.
Anthony Petrone: Sure.
Anthony Petrone: And a real need for a product like this at the same time because of the nature of it you need to grow the business in certain geographical pods, because you make it and deliver it in a short period of time, and so that will take a little bit longer to ramp and then once you start building up that critical mass I think the question is kind of.
Anthony Petrone: Ramp at a significantly faster level, theres, clearly scenarios, where that can take place, it's probably a little bit too early for us to comment on that but I'm Super excited about how Kevin and Eric and his team have delivered at this point in time and we're right on track to what we've laid out to the marketplace.
Anthony Petrone: Thanks Ian.
Ian: Thank you and that does conclude our question and answer session for today's conference I'd now like to turn the call back over to Pete Arduini for any closing remarks.
Ian: So thank you all for joining us today really appreciate the insightful questions. We look forward to connecting with you here in the coming days at one of our upcoming conferences. Thank you very much that concludes our conference call today.
Ian: Thank you for participating in today's conference. This does conclude the program you may now disconnect everyone have a wonderful day.
Ian: Okay.
Ian: [music].
Ian: Yeah.
Ian: [music].
Ian: Yes.
Ian: [music].
Ian: Okay.
Ian: [music].
Ian: Sure.
Ian: [music].
Yes.
Ian: [music].
Ian: Yes.
[music].
Ian: Yes.
Ian: [music].
Ian: Okay.
Ian: Okay.
Ian: Sure.
Ian: Yes.
Ian: Sure.
Ian: [music].
Ian: Sure.
Ian: [music].
Ian: Okay.
Yeah.
Ian: [music].
Ian: Okay.
Ian: Sure.
Ian: [music].
Ian: Sure.
Ian: Okay.
Ian: Okay.
Ian: [music].
Ian: Okay.
Ian: Okay.
Ian: Okay.
Ian: Sure.
Ian: Yes.
Ian: Okay.
Ian: [music].
Ian: Yes.
Ian: Yes.
Ian: Okay.
Ian: Okay.
Ian: Yes.
Ian: Okay.
Ian: Okay.
Ian: Okay.
[music].